Dianthus Therapeutics Reports Q3 2024 Results & Achievements
07 Nov 2024 //
GLOBENEWSWIRE
Dianthus Therapeutics to Attend 3 Upcoming Healthcare Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Dianthus Announces Two Presentations For DNTH103 At AANEM Meeting
15 Oct 2024 //
GLOBENEWSWIRE
Hesperos Supports Phase II Trial with Human-on-a-Chip® Technology
24 Sep 2024 //
BUSINESSWIRE
Dianthus To Attend Three September Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Dianthus Therapeutics Reports Q2 Results And Business Achievements
08 Aug 2024 //
GLOBENEWSWIRE
Dianthus Therapeutics To Present DNTH103 Posters At 10th EAN Congress
28 Jun 2024 //
GLOBENEWSWIRE
Dianthus Therapeutics Announces FDA Clearance For Phase 2 Trial
12 Jun 2024 //
GLOBENEWSWIRE
Dianthus At Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Dianthus Q1 Financials, Highlights Recent Business Achievements
09 May 2024 //
GLOBENEWSWIRE
Dianthus At BofA Securities 2024 Healthcare Conference
08 May 2024 //
GLOBENEWSWIRE
Dianthus Announces Nasdaq Listing Rule Inducement Grants
03 May 2024 //
GLOBENEWSWIRE
Dianthus: DNTH103 Oral Presentation At AAN 2024
11 Apr 2024 //
GLOBENEWSWIRE
Dianthus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2024 //
GLOBENEWSWIRE
Dianthus Highlights Recent Achievements and Reports FY2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Dianthus Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 Mar 2024 //
GLOBENEWSWIRE
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103
26 Feb 2024 //
GLOBENEWSWIRE
Dianthus Therapeutics Announces $230 Million Private Placement
22 Jan 2024 //
PRESS RELEASE
Dianthus to Webcast Presentation at the 42nd J.P. Morgan Healthcare Conference
02 Jan 2024 //
PRESS RELEASE
Magenta sets up Dianthus merger in quick, ending trial due to patient death
03 May 2023 //
ENDPTS
Dianthus Therapeutics appointed Susan Kalled, Ph.D., as Chief Scientific Officer
17 Jan 2023 //
PR NEWSWIRE